Short Description
CF genomics comprises a combination of devices for performing genome-wide expression, genome and methyloma analyses; CF enables spatial genomics and proteomics (3-D biology) for studies of oncogenic signaling pathways and cellular communication processes in healthy and pathological tissues; Device infrastructure: Nanostring GeoMX DSP, Illumina NextSeq 550; Affymetrix Gene Atlas Station; PyroMark Q24 Workstation; RotorQ qPCR machines;
Contact Person
Univ.-Prof. Dr. Fritz Aberger
Research Services
DNA methylation analyses, global and spatial gene expression analyses, exome sequencing; genome sequencing, analysis of signal transduction mechanisms; NA Methylation Analyses, Global Gene Expression Analyses, Exome Sequencing; genome sequencing, analysis of signal transduction mechanisms;
Methods & Expertise for Research Infrastructure
The Core Facility Genomics is used in national and international cooperation projects for the molecular genetic, epigenetic and cell biological/biochemical analysis of biological samples such as heterogeneous cancer tissue and inflammation. The focus is on the genome-wide and spatial investigation of mRNA expression, the analysis of epigenetic modifications such as DNA methylation in cancer cells and DNA sequence analyses in the context of biomedical issues.
Equipment
Salzburg Cancer Research Institute
Department of Life Sciences
University Hospital Salzburg
Cancer Cluster Salzburg
University of Erlangen
University of Göttingen
German Cancer Research Center Heidelberg
University of Vienna
University of Ghent
Ludwig-Maximillian-University (LMU) Munich
University of Linz
Paracelsus Medical University (PMU), Salzburg
2014-2017
Fritz Aberger
Fonds zur Förderung der wissenschaftlichen Forschung: FWF P25629
https://www.fwf.ac.at
Hedgehog-EGFR Signaltransduktion im Basaliom
2008-2011
Fritz Aberger
Fonds zur Förderung der wissenschaftlichen Forschung: FWF P20652
https://www.fwf.ac.at
Targeting E-cadherin - Functional role of E-cadherin shedding in Helicobacter pylori-associated carcinogenesis
2012-2017
Silja Wessler
Fonds zur Förderung der wissenschaftlichen Forschung: FWF P_24074
https://www.fwf.ac.at
Cancer Cluster Salzburg
2017-2020
F. Aberger, J. Horejs-Hoeck, A. Risch, S. Wessler, C. Huber, R. Greil (SALK/PMU, SCRI)
Land Salzburg
www.cancercluster-salzburg.at
Epigenetics of Immunity in cancer (EPIC)
2019-2022
F. Aberger, J. Horejs-Hoeck
EU
www.plus.ac.at/aberger
BIOMED CENTER SALZBURG
2020-2023
F. Aberger
Land Salzburg
www.plus.ac.at/bio
2017
Feng Y, Wang Y, Liu H, Liu Z, Mills C, Han Y, Hung RJ, Brhane Y, McLaughlin J, Brennan P, Bickeboeller H, Rosenberger A, Houlston RS, Caporaso NE, Teresa Landi M, Brueske I, Risch A, Ye Y, Wu X, Christiani DC, Amos CI, Wei Q.
Scientific Reports 2017 Apr 11;7(1):825
DOI: 10.1038/s41598-017-00850-0.
Helicobacter pylori Employs a Unique Basolateral Type IV Secretion Mechanism for CagA Delivery.
2017
Tegtmeyer N, Wessler S, Necchi V, Rohde M, Harrer A, Rau TT, Asche CI, Boehm M, Loessner H, Figueiredo C, Naumann M, Palmisano R, Solcia E, Ricci V, Backert S.
Cell Host & Microbe 2017 Oct 11;22(4): 552-560.e5
DOI: 10.1016/j.chom.2017.09.005.
Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells
2012
Eberl M, Klingler S, Mangelberger D, Loipetzberger A, Damhofer H, Zoidl K, Schnidar H, Hache H, Bauer HC, Solca F, Hauser-Kronberger C, Ermilov AN, Verhaegen ME, Bichakjian CK, Dlugosz AA, Nietfeld W, Sibilia M, Lehrach H, Wierling C, Aberger F.
EMBO Molecular Medicine
DOI: 10.1002/emmm.201100201
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity
2020
Sandra Grund-Gröschke, Daniela Ortner, Antal B Szenes-Nagy, Nadja Zaborsky, Richard Weiss, Daniel Neureiter, Martin Wipplinger, Angela Risch, Peter Hammerl, Richard Greil, Maria Sibilia, Iris K Gratz, Patrizia Stoitzner, Fritz Aberger
Mol. Oncology
DOI: 10.1002/1878-0261.12758
Context-dependent modulation of aggressiveness of pediatric tumors by individual oncogenic RAS isoforms.
2021
Bauer J, Cuvelier N, Ragab N, Simon-Keller K, Nitzki F, Geyer N, Botermann DS, Elmer DP, Rosenberger A, Rando TA, Biressi S, Fagin JA, Saur D, Dullin C, Schildhaus HU, Schulz-Schaeffer W, Aberger F, Uhmann A, Hahn H.
Oncogene
DOI: 10.1038/s41388-021-01904-4
DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer
2018
Gampenrieder SP, Rinnerthaler G, Hackl H, Pulverer W, Weinhaeusel A, Ilic S, Hufnagl C, Hauser-Kronberger C, Egle A, Risch A, Greil R..
Theranostics
doi: 10.7150/thno.23544